Tachycardia-Induced Cardiomyopathy by Riedlbauchova, Lucie
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Tachycardia-Induced Cardiomyopathy
Lucie Riedlbauchova
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/60716
Abstract
Virtually, any kind of tachycardia may lead to the development of tachycardia-
induced cardiomyopathy. This term refers to left ventricular dysfunction and dilated
cardiomyopathy pattern that occur as a consequence of persistent tachycardia.
Impaired left ventricular function in the presence of tachycardia can be found
accidentally, but it is often associated with progressive symptoms and signs of heart
failure that force the individual to seek medical help. A hallmark of tachycardia-
induced cardiomyopathy is the reversibility of both hemodynamic and structural
changes after cessation of the index tachycardia. However, contractile dysfunction
and structural changes may persist even weeks after the rhythm/rate correction.
Therefore, tachycardia-induced cardiomyopathy should be considered as a probable
reason of ventricular dysfunction and dilatation in any patient presenting with dilated
cardiomyopathy pattern, despite that the initial rhythm is not pathological or the heart
rate is well controlled. This review summarizes our current knowledge about this
specific form of cardiomyopathy.
Keywords: tachycardia-induced cardiomyopathy, arrhythmia, tachycardia, heart
failure, dilated cardiomyopathy
1. Introduction
Cardiomyopathies represent a heterogenous group of myocardial diseases in which the
myocardium exhibits structural and/or functional dysfunction [1, 2]. Current definition of
cardiomyopathies excludes structural myocardial processes and dysfunction secondary to
specific cardiovascular disorders such as coronary artery disease, systemic arterial hyperten‐
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sion, congenital heart diseases or valvular diseases. Although tachycardia-induced cardiomy‐
opathy may be seen as secondary due to well-defined causal cardiovascular factor, this
disorder ranks among cardiomyopathies also in the current definition and classification of
cardiomyopathies [1, 2].
Tachycardia-induced cardiomyopathy is a disease with attributes of dilated cardiomyopathy
that develop as a consequence of persistent tachycardia. It is characterized by systolic ventric‐
ular dysfunction and dilatation with heart failure symptoms that occur as a result of long-term
tachycardia of either supraventricular or ventricular origin. This disease should be also
considered as a cause of ventricular dysfunction in the absence of tachycardia at the time of
patient presentation since the tachyarrhythmia could disappear spontaneously before the
initiation of patient examination, while the hemodynamic and especially structural changes
of the heart induced by long-term tachycardia may persist even weeks after arrhythmia
disappearance and/or rate control achievement.
The key feature of tachycardia-induced cardiomyopathy is the reversibility of both functional
and structural changes as soon as the heart rate/rhythm is well controlled. In such case,
improvement or even complete functional and structural normalization may be found. A
correct diagnosis is thus often stated retrospectively based on the observation of ventricular
systolic function improvement and regression of ventricular dilatation after appropriate rate/
rhythm control.
2. Incidence, prevalence and prognosis
Although tachycardia-induced cardiomyopathy is considered to be a relatively rare instance,
its precise incidence is not described well yet. In fact, this disease is very likely to be under‐
diagnosed in the clinical practice despite that the link between tachycardia and dilated
cardiomyopathy pattern has been known for a long time [3-5]. One reason for its underesti‐
mation may be the uncertainty whether the detected tachycardia is the primary cause of the
cardiomyopathy, or whether it is rather a consequence of cardiomyopathy of different origin.
Tachycardia-induced cardiomyopathy may develop at any age. It has been documented in
fetuses with persistent supraventricular tachycardias [6], in children and adolescents [7] as
well as in adults [8].
Virtually, any type of arrhythmia is capable of inducing ventricular dysfunction or cardiomy‐
opathy; however, supraventricular arrhythmias are the most commonly reported causes of
tachycardia-induced cardiomyopathy. It has been predominanly described in association with
atrial fibrillation, but other supraventricular arrhythmias may lead to this pathology too.
Tachycardia-induced cardiomyopathy may also develop as a result of persistent ventricular
tachycardia, rapid atrial and/or ventricular pacing or as a consequence of some extracardiac
diseases that are associated with persistent tachycardia (Table 1). Importantly, it may also occur
in patients with "only” frequent ventricular premature beats [9].
Atrial fibrillation  (the most frequently reported arrhythmia associated with tachycardia-
induced cardiomyopathy development) is a frequent type of supraventricular tachycardia
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in patients with dilated cardiomyopathy and heart failure. It appears that there is a close
relationship  between  atrial  fibrillation  and  heart  failure:  heart  failure  progression  sup‐
ports electrical and structural remodeling of the heart, which finally leads to atrial fibrilla‐
tion  development.  On  the  other  hand,  epidemiological  studies  have  demonstrated  that
patients with atrial fibrillation are at higher risk of heart failure [10] and that abnormal left-
ventricular systolic function is 2.5 times more likely in elderly patients (> 65 years) with
atrial  fibrillation  than  in  those  without  this  arrhythmia  [11].  In  addition,  sinus  rhythm
restoration or adequate rate control of ongoing arrhythmia are associated with the improve‐
ment or even normalization of left-ventricular ejection fraction in some of these patients.
These findings indicate that at least in some cases, left-ventricular dysfunction is primari‐
ly caused by rapid heart rate during atrial  fibrillation rather than by preexisting dilated
cardiomyopathy. Moreover, some studies indicate that approximately 25–50% of patients
with atrial fibrillation, who simultaneously suffer from ventricular dysfunction, have some
degree of tachycardia-induced cardiomyopathy [12, 13].
Another instance of tachyarrhythmia that used to be associated with a relatively higher
prevalence of cardiomyopathy pattern is atrial flutter. Some observational studies indicated
that left-ventricular systolic dysfunction is present in up to 25% of patients reported to atrial
flutter ablation, and in more than half of these, it is possible to observe a significant improve‐
ment or even normalization of ejection fraction during the first twelve months after successful
elimination of the tachycardia [14].
Prevalence of ventricular dysfunction is relatively high also in incessant atrial tachycardia,
since it has been reported in approximately 10–19% of cases [15, 16]. It seems that children are
more susceptible to tachycardia-induced cardiomyopathy than adults. Among adults,
tachycardia-induced cardiomyopathy appears to be present more often in younger adult
patients with persistent atrial tachycardia than in those of a higher age, although the lower
Supraventricular
arrhythmias
Atrial fibrillation [13, 73]
Atrial flutter [14, 74]
Focal atrial tachycardia [15, 16]
AVNRT [17, 18]
AVRT [19, 75]
Permanent junctional reciprocating tachycardia (PJRT) [20]
Ventricular arrhythmias
Frequent ventricular premature beats (VPBs) [9, 76]
Idiopathic right or left ventricular outflow tract tachycardia [7, 8]
Bundle-branch reentry ventricular tachycardia [77]
Cardiac pacing Atrial pacing at high rates [30]Ventricular pacing at high rates [32]
Extracardiac causes Thyreotoxicosis [78]Glucagonoma [79]
Myocarditis [80]
Table 1. Disorders associated with tachycardia-induced cardiomyopathy development (adapted from [81])
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prevalence in the older population may be partially caused by difficulties to distinguish the
effect of tachycardia alone from that of the underlying heart disease with regard to the systolic
ventricular function. Interestingly, elimination of the arrhytmia leads to the restoration of left-
ventricular function in up to 97% [16].
Supraventricular reentrant tachycardias (atrioventricular nodal reentry tachycardia
(AVNRT) and atrioventricular reciprocating tachycardia (AVRT)) have usually only paroxys‐
mal nature. If persistent, these may also induce cardiomyopathy and heart failure that are
reversible after catheter ablation [17-20].
Ventricular tachycardias are usually associated with some forms of underlying structural
heart diseases. Therefore, it is difficult to distinguish whether and to what extent is the
observed systolic ventricular dysfunction caused by the primary disease, and how much has
persistent tachycardia contributed to its severity. This may be determined more precisely in
patients with idiopathic ventricular tachycardias, which (if persistent or repetitive enough)
may lead to cardiomyopathy. Restoration of normal systolic performance of the left ventricle
has been described in patients with successful elimination of both right-ventricular outflow
tract tachycardia [8] and left-ventricular outflow tract tachycardia [7].
However, cardiomyopathy with or without symptomatic heart failure may be present also
in patients with ”only” frequent premature beats. It has been described mainly in patients
with frequent ventricular ectopy [9, 21-23], but high burden of atrial premature beats may
also  lead  to  reversible  cardiomyopathy  [24,  25].  A  prospective  multicenter  study  that
included patients with reduced left-ventricular ejection fraction due to suspected ventricu‐
lar premature beat-associated cardiomyopathy has found that both systolic function and
neurohumoral  response  (levels  of  natriuretic  peptide)  improve as  soon as  the  ectopy is
successfully eliminated and that the extent of improvement is comparable between patients
with and without known structural  heart  disease [26].  These authors suggested that  the
higher the burden of ventricular premature beats (VPB), the higher the probability of systolic
function improvement after ectopy elimination, with 13% baseline VPB burden being 100%
sensitive and 85% specific to predict left-ventricular ejection fraction increase by ≥5% after
elimination of the ectopic focus. Although not confirmed in all studies [26], some research‐
ers  have  also  suggested  that  the  QRS  duration  of  VPB  is  an  important  factor  in  the
development  of  cardiomyopathy,  with  wider  QRS  complexes  more  likely  to  lead  to
cardiomyopathy pattern with  a  lower  total  burden of  PVBs [27,  28]  and that  epicardial
origin of VPBs is also associated with delayed LV function recovery [29].
Prognosis of dilated cardiomyopathy may vary depending on the cause. Tachycardia-induced
cardiomyopathy ranks among forms of dilated cardiomyopathy with (if treated appropriately)
generally good prognoses. Although studies describing recovery of patients with tachycardia-
induced cardiomyopathy after sinus rhythm restoration or rate control include only small
samples of patients, it appears that these causal therapeutic options may result in an improve‐
ment of left-ventricular function, positive change in neurohumoral cascade (reduced levels of
natriuretic peptides) [26] and that it is likely to be linked to a generally good prognosis of
tachycardia-induced cardiomyopathy.
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3. Pathogenesis
Our current knowledge about the pathogenesis of tachycardia-induced cardiomyopathy is
predominantly based on animal models that have been introduced to study heart failure
[30-35]. In these experiments, heart failure is induced by rapid cardiac pacing of certain
duration, at the atrial and/or ventricular level. Hemodynamic changes that result from such
pacing strongly resemble findings in humans [31-35]. Similar abnormalities have been also
identified in animals with ”only” ventricular premature beats delivered artificially in bigemi‐
nal pattern, and these changes are reminiscent of those in humans as well [36]. Observations
proving that all these alterations are fully or at least partially reversible with cessation of
tachycardia also correspond with results found in humans [32, 37].
Figure 1. Tachycardia-induced cardiomyopathy in a 38-years old male with no previous history of any heart disease or
arrhythmia. First episode of persistent atrial fibrillation with rapid heart rate (1a, 1b) in his life caused progressive de‐
terioration of ventricular systolic function leading to clinical manifestation of heart failure during 4 weeks. 1c shows
significantly reduced ejection fraction of the left ventricle with its incipient enlargement during the tachycardia. Both
heart failure symptoms and left-ventricular systolic function rapidly improved during the following 3 weeks after si‐
nus rhythm restoration (2a). Size and systolic function of the left ventricle then almost normalized in the horizon of 3
months after the tachycardia termination (2b).
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3.1. Hemodynamic changes
Rapid atrial or ventricular pacing in experimental models leads to biventricular systolic and
diastolic dysfunctions that occur relatively early after the onset of tachycardia [38, 39]. Typical
findings include reduced systolic function of both ventricles reaching up to 55%, decline in
cardiac output, elevation of ventricular filling pressures, systemic vascular resistance as well
as ventricular systolic wall stress [33-35, 40, 41]. Systolic ventricular dysfunction is caused by
the loss of contractility. In addition, contractile reserve in response to volume, inotropic agents
or post-extrasystolic potentiation is affected [42, 43] and myocardial relaxation is impaired [44].
As a consequence of altered hemodynamic situation, mitral regurgitation may develop in
longer-term perspective that leads to volume overload of the failing heart [45].
3.2. Structural changes
Persistent tachycardia, either induced artificially by chronic cardiac pacing or resulting from
persistent tachyarrhythmia, finally leads to the dilatation of all cardiac chambers. Left ventricle
increases both its end-systolic and end-diastolic volume (with end-systolic volume being
affected more [33, 34]) and it further changes its geometry to a spherical shape [46]. This
dilatation is usually associated with wall thinning or preservation of wall thickness without
either increased heart weight or hypertrophy [45, 46].
On microscopical level, remodeling of both cardiomyocytes and extracellular matrix may be
detected: disruptions of sarcolemma-basement membrane interface, myofibrillar misalign‐
ment, cellular elongation and myocyte loss (up to 39% of the total myocyte mass) have been
found [40, 47, 48]. Architecture of the extracellular matrix is usually remarkably modified as
well and this also contributes to myocyte misalignment and adversely affects force coupling
and transmission.
In addition to functional and structural changes, electrophysiologic remodeling has been
documented. Abnormal functioning of calcium channels, stretch-sensitive channel dysfunc‐
tion and other abnormalities often affect and prolong repolarization that can finally result in
ventricular tachycardias manifestation [49].
3.3. Neurohumoral changes
Similar to other forms of heart failure, marked neurohumoral activation occurs and leads to
elevated plasma levels of natriuretic peptides, epinephrine, norepinephrine, aldosterone and
renin activity [39]. Downregulation of beta-1 receptor density with the resulting decrease in
beta-adrenergic responsiveness have been found as well [50, 51].
All the above-mentioned hemodynamic, structural and neurohumoral changes have been
demonstrated also in humans, which supports the conclusion that pacing-induced model
of  heart  failure  could  be  a  useful  tool  to  study  pathogenesis  of  tachycardia-induced
cardiomyopathy.
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3.4. Pathophysiology of tachycardia-induced cardiomyopathy
The development of tachycardia-induced myocardial dysfunction appears to be a result of
multiple factors.  Various alternations of neurohumoral and cellular activation have been
identified;  however,  it  is  still  uncertain  whether  they  represent  the  causal  factor  of  the
functional  and subsequent  structural  changes  in  all  cases,  or  whether  they  are  rather  a
consequence of tachycardia. Although the precise mechanism behind contractile dysfunc‐
tion  with  the  resulting  structural  changes  is  not  fully  understood yet,  the  research  has
focused mainly on three potential factors: 1) depletion of high-energy stores in the myocardi‐
um with impaired energy utilization, 2) myocardial ischemia and 3) abnormality in calcium handling.
On  subcellular  level,  persistent  tachycardia  leads  to  energy-stores  depletion,  which  is
associated  with  the  reduction  of  adenosin-triphosphate  (ATP),  phosphocreatinine  and
creatinine levels in the myocardium. In addition, a reduced activity of the Na/K-ATPase
pump has been described [52, 53a, 53b]. It is very likely due to enhanced activity of Krebs
cycle oxidative enzymes and mitochondrial injury [40, 41].
Similar findings have been described in the case of myocardial ischemia. In the ischemic model,
rapid depletion of energy-stores and left-ventricular dysfunction occur shortly after vessel
occlusion [54]. However, their return to normal values lasts mostly about days long after the
ischemic attack, which also corresponds with findings in tachycardia-induced cardiomyop‐
athy where altered hemodynamic and structural changes resolve in prolonged time interval.
Proceeding from these facts, myocardial ischemia is considered to be a potential factor that
contributes to the tachycardia-induced cardiomyopathy development. In fact, abnormal
coronary flow and changed ratios of subendocardial and subepicardial flow have been
observed in tachycardia-induced cardiomyopathy [55, 56].
The hypothesis that abnormal handling of calcium plays a role in the genesis of tachycardia-
induced cardiomyopathy has received substantial support, because the severity of calcium
cycling abnormalities has been shown to correlate with the extent of ventricular dysfunction
[41]. Abnormal calcium handling occurs already in the first 24 hours of rapid cardiac pacing
and it may persist for more than 4 weeks after tachycardia termination [41]. Altered functions
of calcium channels and transport system of the sarcoplasmatic reticulum have been identified
[41, 57] and they may thus contribute to myocardial dysfunction observed in tachycardia-
induced cardiomyopathy due to lower calcium availability to myocytes with the resulting
contractility reduction. Some other studies suggest altered calcium-sensitivity and excitation-
contraction coupling [57, 58].
An observation that tachycardia-induced cardiomyopathy does not evolve in every patient
with the same type, duration and rate of a tachycardia implies possible genetic predisposition of
some patients to develop a dilated cardiomyopathy pattern during tachycardia. In fact, one
study [59] suggests that polymorphism in angiotensin-converting enzyme (ACE) gene may be
involved, since one type of such polymorphism (which is associated with higher serum levels
of ACE) is more frequently linked to idiopathic and ischemic cardiomyopathy manifestation.
Looking at the prevalence of this polymorphism among 20 patients with tachycardia-induced
cardiomyopathy as compared to another sample of 20 patients without this pattern, the authors
reported a higher detection of this ACE polymorphism in the cardiomyopathic group [59].
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3.5. Course of the changes over time and their reversibility
Experimental studies demonstrate that changes of hemodynamics with the reduction of
cardiac output or altered systemic arterial pressure occur already in the first 24 hours of rapid
pacing [32]. When continued, fast cardiac pacing then induces an elevation of ventricular filling
pressures, pulmonary artery pressure and a decrease of systemic arterial pressure that reach
certain plateau after one week, while cardiac output, volumes and ejection fraction deteriorate
continually for 3–5 weeks with the final end-stage heart failure development [35, 45].
Cessation of tachycardia results in a resolution of these changes: in the first 48 hours after
termination of cardiac pacing, a significant improvement of cardiac output, systemic vascular
resistance, mean arterial pressure and filling pressures are present [39]. Left-ventricular
ejection fraction also improves dramatically and normalizes within 1–2 weeks [39]. All
hemodynamic variables normalize within the horizon of four weeks after tachycardia inter‐
ruption, but diastolic dysfunction remains detectable even after the first month period.
Importantly, elevated end-diastolic and end-systolic volumes are still present after twelve
weeks of pacing discontinuation, which is consistent with substantial ventricular remodeling
[33, 46], that requires longer time for its resolution.
Although the hallmark of tachycardia-induced cardiomyopathy is an improvement or even
normalization of cardiac function and size with the resulting disappearance of heart failure
symptoms after cessation of tachycardia or rate control achievement, there is growing evidence
that the ultrastructural abnormalities of the myocardium and residual contractility dysfunc‐
tion may persist. This has already been suggested in the experimental studies [53b], but similar
conclusions have also been made in clinical observational reports [60, 61]. In one of these
studies, ventricular function has been assessed using specle tracking and contrast-enhanced
MRI with ventricular T1 mapping used as an index of diffuse fibrosis. Although the ejection
fraction normalized three months after a successful ablation of initial tachycardia already, it
has been possible to detect a somewhat greater indexed end-diastolic and end-systolic volume
of the left ventricle in patients with tachycardia-induced cardiomyopathy as compared to
healthy controls. Moreover, patients with previous tachycardia-induced cardiomyopathy
have demonstrated reduced global left-ventricular corrected T1 time that implies a diffuse
fibrosis [61]. In addition, another study [60] suggests that tachycardia tends to recur in some
patients initially diagnosed with tachycardia-induced cardiomyopathy pattern and this
recurrence of arrhythmia leads to a new decline of systolic ventricular function. Moreover,
sudden death may occur in some of these patients despite normal or almost normal systolic
function during the last evaluation [60].
4. Clinical manifestation and diagnosis
It is important to consider tachycardia-induced cardiomyopathy in all cases as a possible cause
of systolic dysfunction and manifest heart failure, especially in patients with a new or wors‐
ened ventricular systolic dysfunction or in cases with their uncertain duration in which
persistent tachycardia is found simultaneously. Since contractile dysfunction and structural
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changes may persist even weeks after the rhythm/rate correction, tachycardia-induced
cardiomyopathy should be considered as a probable reason of ventricular dysfunction and
dilatation in any patient presenting with dilated cardiomyopathy pattern, despite that the
initial rhythm is not pathological or the heart rate is well controlled.
Generally, persistent tachycardia (i.e. tachycardia lasting usually weeks or months) predis‐
poses an individual to ventricular dysfunction and dilatation development, regardless of the
rhythm disturbance characteristics. However, the resulting degree of systolic dysfunction and
heart dilatation, the rate of their progression and the reversibility of hemodynamic and
structural abnormalities after rhythm/rate correction are partially dependent on the heart rate,
type and duration of the tachycardia and also on the concomitant presence of other heart
diseases. In addition, there is growing evidence that irregularity of the rhythm alone may
contribute to these changes manifestation and that it may also affect the rate and the extent of
their resolution after rhythm correction.
Heart rate is apparently one of the most important factors. Tachycardia-induced cardiomy‐
opathy is rate dependent: tachycardias with higher rates manifest themselves usually earlier
than those with slower rates [31, 62]. In an experimental setting, pacing at slower rate or for a
shorter time usually yields a lesser degree of left-ventricular systolic dysfunction [39, 63].
However, some observational studies imply that tachycardia-induced cardiomyopathy may
be found more often in patients with a slower heart rate than in those with a higher rate. This
was reported in retrospective observational studies that included patients referred to cathe‐
terization ablation of focal atrial tachycardia [15, 16]. Tachycardia-induced cardiomyopathy
was present in 9–19% of these cases, more frequently in patients with heart rate of less than
120 bpm. Possible explanation for this finding may include the fact that faster tachycardia is
associated with early symptom manifestation in form of palpitation, whereas tachycardias
with lower heart rate are better tolerated by the patient, so the remodeling and signs of heart
failure have enough time to develop before the patient visits a doctor.
How fast does the tachycardia have to be to induce tachycardia-induced cardiomyopathy is
still not clear. Basically, any rhythm with the rate exceeding 100 bpm for a longer period of
time may lead to this pathology. In this context, it is important to note that heart rate (especially
in atrial fibrillation) may vary significantly as a result of physical or mental activity, i.e. patients
may show well-controlled heart rate at rest that increases abnormally during minimal exercise.
Therefore, Holter ECG monitoring may be useful to identify such behavior and to raise
suspicion of tachycardic origin of an observed ventricular dysfunction. Cut-offs for adequate
rate control have been derived from atrial fibrillation patients. They generally vary with age,
but heart rate ranging between 60 and 80 bpm at rest and 90–115 bpm during a moderate
exercise are usually considered as adequate (so-called strict rate control) [64]. These target rates
are sometimes difficult to achieve, however. A lenient rate control strategy [65] aiming at
resting heart rate <110 bpm seems to have similar long-term results as the strict rate control of
atrial fibrillation and is thus preferred nowadays.
In the experimental model, persistent ventricular tachyarrhythmias induce generally more
significant ventricular dysfunction than supraventricular tachycardias [38].
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Tachycardia-induced cardiomyopathy may develop in a variable time-horizon since the
tachycardia onset (even after many months). Together with heart rate and type of the arrhyth‐
mia, the tachycardia duration is responsible for the severity and reversibility of ventricular
systolic dysfunction [31] as it has been discussed earlier.
Tachycardia-induced cardiomyopathy can be present as either sole pathology or it may
accompany another heart disease. It means that the presence of other structural heart disease
does not exclude concurrent presence of tachycardia-induced cardiomyopathy. In these cases,
tachycardia may worsen the pre-existing ventricular dysfunction and dilatation [12]. The
degree of a ventricular dysfunction is then usually inadequate to the severity of the underlying
heart disease (i.e. atherosclerotic changes of the coronary arteries). Tachycardia-induced
cardiomyopathy is highly probable especially in patients with recently normal systolic
function of the ventricles and in those with an improvement of dysfunction after the achieve‐
ment of an adequate rate/rhythm control.
Another factor which appears to contribute to tachycardia-induced cardiomyopathy is the
irregularity of a rhythm. It is based not only on the observations that frequent ectopic
supraventricular or ventricular beats are able to induce the pattern of reversible dilated
cardiomyopathy [9, 22, 24], but also on studies on rate control in atrial fibrillation [66], which
demonstrate that the irregularity of a fast rhythm may worsen cardiac function whereas it does
not cause any significant hemodynamic worsening if the heart rate of the irregular rhythm
falls generally within a normal range.
Assessment of a patient with suspected tachycardia-induced cardiomyopathy includes a
detailed history and physical examination with the subsequent laboratory and imaging tests
to state the diagnosis and severity of the disease.
4.1. Symptoms and signs
The manifestation of tachycardia-induced cardiomyopathy is various. The most common
symptoms include palpitations and signs of heart failure. Palpitations resulting from either
high rate or irregularity of the arrhythmia are often the dominant complaint of a patient with
fast tachycardia. These patients thus often consult a doctor early in search of intervention and
cardiomyopathy pattern then does not have enough time to develop. On the other hand,
symptoms and signs of a heart failure may predominate in those patients who do not feel
palpitation and are not aware of a rhythm disturbance. In such patients, decreased exercise
capacity, fatigue or congestion may be the main complaint.
Due to the fact that acuteness of the symptoms forces a patient with rapid heart rate to seek
medical help shortly after the arrhythmia onset, some scholars hypothesize that tachycardia-
induced cardiomyopathy is present rather in patients with slower arrhythmias. Some clinical
observations support such conclusions [15, 16]: The first retrospective observational study [16]
included a sample of 331 patients without structural heart diseases who underwent ablation
of atrial tachycardia. Tachycardia-induced cardiomyopathy was present in 9% of them and
affected rather younger patients (mean age 39 vs. 51 years), more often males (60% versus 38%)
with incessant or very frequent paroxysmal tachycardia (100% vs. 20%) with a slower heart
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rate (120 bpm vs. 149 bpm), than arrhythmias that have not been associated with ventricular
dysfunction. Similar findings have been reported also in children with persistent atrial
tachycardias [15]: atrial tachycardia originating within the atrial appendage was more often
associated with slower heart rate (<120 bpm) at examination, asymptomatic course (75% versus
25%) and higher prevalence of tachycardia-induced cardiomyopathy as compared to atrial
tachycardia of other origins.
In all other aspects, tachycardia-induced cardiomyopathy resembles other forms of dilated
cardiomyopathy: symptoms and signs of heart failure, their severity as well as neurohumoral
activation are principally similar.
4.2. Diagnosis
As soon as tachycardia-induced cardiomyopathy is suspected, tests that aim to confirm the
diagnosis take place.
All patients should have 12-lead ECG to document basic heart rhythm and its rate at patient
presentation. Especially in cases with persistent atrial tachycardia, it is helpful to compare
recent ECG tracing with an older one (if available) to distinguish whether the current P wave
morphology corresponds with the documented sinus rhythm morphology or if it is rather
suggestive for atrial focus. Since the heart rate may change over time, due to mental or physical
activity, patients with suspected tachycardia-induced cardiomyopathy should undergo
continuous ECG monitoring for at least 24 hours (ambulatory Holter ECG monitoring or in-
patient telemetry). If uncertainty regarding the underlying rhythm persists, electrophysiologic
testing should be considered.
Besides arrhythmia detection, the presence of left-ventricular dysfunction with/without
ventricular dilatation should be documented. With this regard, transthoracic echocardiogra‐
phy represents a gold standard. Morphological findings are principally similar as in the dilated
cardiomyopathy of other origins and differentiation between tachycardia-induced cardiomy‐
opathy and other forms of dilated cardiomyopathy is generally not possible based on the
echocardiographic pattern only, although left-ventricular end-diastolic diameter tends to be
usually smaller in cases of tachycardia-induced cardiomyopathy [67].
Despite that the patient presents with tachyarrhythmia, other reasons of dilated cardiomyop‐
athy pattern should be therefore considered as soon as the ventricular dysfunction and
dilatation is documented at any imaging modality. Adult patients are thus often indicated to
coronary angiography to exclude the most common substrate of ventricular dysfunction, i.e.
a significant underlying coronary artery disease. History of alcohol intake, drug abuse, cancer
and its treatment, thyreopathy or other metabolic or congenital disease should be searched for
further.
A single-center experience suggests that also serial NT-pro BNP measurement may be useful
to distinguish between tachycardia-induced cardiomyopathy and cardiomyopathies due to
structural heart disease [68]. This study included patients who presented with supraventric‐
ular tachycardia and reduced left-ventricular ejection fraction <40% and underwent cardio‐
version. The NT-pro BNP level has initially been elevated in all patients. After a successful
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cardioversion, NT-pro BNP has decreased in virtually all patients, but the decrease has been
quicker in tachycardia-induced cardiopmyopathy patients. Therefore, the ratio between the
baseline NT-pro BNP and NT-pro BNP after one week following cardioversion ≥ 2.3 has had
90% sensitivity, 95% specificity and 90% accuracy to predict tachycardia-induced origin of
ventricular dysfunction based on these authors.
5. Therapy
Therapeutic  approach to the tachycardia-induced cardiomyopathy includes two steps:  1.
tachyarrhythmia  correction  as  it  represents  causal  therapeutic  intervention  and  2.  heart
failure treatment.
Due to the potential reversibility of hemodynamic and structural changes in tachycardia-
induced cardiomyopathy, all efforts should be made to achieve heart rate correction or
appropriate rate control. Rhythm or rate control may be achieved using both pharmacological
and non-pharmacological tools. Depending on the type of arrhythmia and presence/absence
of concomitant structural heart disease, various antiarrhytmic drugs may be used to terminate
the arrhythmia or to achieve adequate rate control. Especially, betablockers and class III
antiarrhythmics play an irreplaceable role regarding this treatment. It is very important to
avoid drugs with higher pro-arrhythmic effect (e.g. flecainide) in the presence of systolic
dysfunction or drugs that may contribute to further progression of systolic dysfunction (e.g.
disopyramide). Most arrhythmias that lead to tachycardia-induced cardiomyopathy are
currently treatable using catheterization ablation, success rate of which reaches 60–90%
depending on the type of arrhythmia. This therapeutic approach should be therefore consid‐
ered as a first-line treatment in the absence of contraindication.
In atrial fibrillation, rate and rhythm control strategy have been shown to be comparable with
respect to quality of life, mortality or stroke rate [64, 69]. The decision to favor rhythm control
over rate control should thus be made on an individual basis, and discussed with the patient
[70]. In case rate control strategy is chosen, repeated long-term ECG monitoring is instrumental
to decide whether the selected treatment is appropriate and ensures acceptable rate control
(strict rate control requires 60–80 bpm at rest and 90–115 bpm at moderate exercise; lenient
rate control requests resting rate < 110 bpm). Atrial arrhythmias are often refractory to
antiarrhythmic drugs and an acceptable rate control may be then achieved only with higher
doses of AV nodal blocking agent. In such cases, catheter ablation is an option. By other
supraventricular tachyarrhythmias, which lead to tachycardia-induced cardiomyopathy,
restoration of sinus rhythm is usually preferred. Rhythm correction may be achieved through
either pharmacological or electrical cardioversion or (preferably) via catheter ablation of the
arrhythmia in these patients.
In rare cases, failing to restore sinus rhythm (even using catheter ablation) and to achieve
adequate ventricular control, an ablation of AV node with insertion of a permanent pacemaker
may be considered. Because of the present ventricular dysfunction prior to pacemaker
insertion, biventricular systems are usually favored [71].
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Treatment of heart failure symptoms due to tachycardia-induced cardiomyopathy includes
standard regimen and drug spectrum as in heart failure of other origin, i.e. ACE inhibitors,
beta-blockers, angiotensin-receptor blockers, diuretics and digoxin.
6. Risk of tachycardia-induced cardiomyopathy recurrence
Similarly as in the experimental models, improvement of ventricular systolic function may be
often found in one week horizon and full recovery (including chamber size reduction), usually
over a time period of 4–6 weeks after rhythm/rate correction. In some patients, size of the left
ventricle may remain slightly enlarged [72].
Although there are no recommendations regarding follow-up of the patients who once
experienced tachycardia-induced cardiomyopathy, it is advisable to observe such patients
closely for at least one or two years after the initial manifestation. The reason for it is certain,
although not specifically determinable risk of arrhythmia recurrence that may induce new and
rapid decrease of left-ventricular ejection fraction despite cardiomyopathy could develop
within months during the initial episode. Patients experiencing the recurrence of tachycardia-
induced cardiomyopathy are at higher risk of sudden death [72] and implantation of an ICD
may be thus considered in these cases.
7. Conclusion
The difficulties to differentiate reliably between tachycardia-induced cardiomyopathy and
other forms of dilated cardiomyopathy, and the fact that the correct diagnosis is often estab‐
lished only retrospectively based on the improved systolic function after heart rate correction
are the two most important reasons why the real prevalence of tachycardia-induced cardio‐
myopathy may be much higher than it is currently reported. Since it is a potentially reversible
cause of heart failure, it is very important to always consider this option in the concomitant
presence of dilated cardiomyopathy pattern and persistent tachycardia. An early heart rate
intervention may then have substantial clinical impact.
Although experimental studies helped us to understand the basic pathophysiologic process
behind the tachycardia-induced cardiomyopathy development, there is still a number of
questions that need to be answered. For example, it is not clear why the tachycardia-induced
cardiomyopathy does not occur in all patients with persistent tachycardia of the same type
and heart rate. Furthermore, it is not clear whether or not are the patients who once developed
tachycardia-induced cardiomyopathy in their life more susceptible to heart failure of another
origin in the long-term perspective, similarly as are women with gestational diabetes more
prone to develop the second type of diabetes in their future life. In addition, the exact patho‐
physiology behind tachycardia-induced cardiomyopathy is still not well understood. All these
and other questions should therefore become the subjects of future research.
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